This is a working overview of freeze-dried powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
The oldest known pills were made of the zinc carbonates hydrozincite and smithsonite. The pills were used for sore eyes and were found aboard the Roman ship Relitto del Pozzino, wrecked in 140 BC. The Berne zinc tablet is a votive plaque dating to Roman Gaul made of an alloy that is mostly zinc. The Charaka Samhita, thought to have been written between 300 and 500 AD, mentions a metal which, when oxidized, produces pushpanjan, thought to be zinc oxide. Zinc mines at Zawar, near Udaipur in India, have been active since the Mauryan period (c. 322 and 187 BC). The smelting of metallic zinc here, however, appears to have begun around the 12th century AD. One estimate is that this location produced an estimated million tonnes of metallic zinc and zinc oxide from the 12th to 16th centuries. Another estimate gives a total production of 60,000 tonnes of metallic zinc over this period. The Rasaratna Samuccaya, written in approximately the 13th century AD, mentions two types of zinc-containing ores: one used for metal extraction and another used for medicinal purposes.
In 1939, the Soviet Union and Nazi Germany agreed to the Treaty of Non-aggression between Germany and the Union of Soviet Socialist Republics (Molotov–Ribbentrop Pact, 23 August 1939) and to jointly invade and partition Poland, by way of which Nazi Germany started the Second World War (1 September 1939). In the 1941–1942 period of the Great Patriotic War, the German invasion of the Soviet Union (Operation Barbarossa, 22 June 1941) was ineffectively opposed by the Red Army, who were poorly led, ill-trained and under-equipped. As a result, they fought poorly and suffered great losses of soldiers (killed, wounded and captured). The weakness of the Red Army was partly consequence of the Great Purge (1936–1938) of senior officers and career soldiers whom Stalin considered politically unreliable. Strategically, the Wehrmacht's extensive and effective attack threatened the territorial integrity of the Soviet Union and the political integrity of Stalin's model of a communist state, when the Nazis were initially welcomed as liberators by the anti-communist and nationalist populations in the Byelorussian Soviet Socialist Republic, the Georgian Soviet Socialist Republic and the Ukrainian Soviet Socialist Republic. The anti-Soviet nationalists' collaboration with the Nazi's lasted until the Schutzstaffel and the Einsatzgruppen began their Lebensraum killings of the Jewish populations, the local communists, the civil and community leaders—the Holocaust meant to realise the Nazi German colonisation of Bolshevik Russia.
There are various preparations of gonadotropins for therapeutic use, mainly as fertility medication. For example, the so-called menotropins (also called human menopausal gonadotropins) consist of LH and FSH extracted from the urine of menopausal women. There are also recombinant variants. Besides the aforementioned legitimate pharmaceutical drugs, there are fad diet or quack preparations, which are illegal in various countries.
== Biosynthesis == Prostaglandin E1 is biosynthesized on an as-needed basis from dihomo-γ-linolenic acid (an omega-6 fatty acid) in healthy humans without coronary artery disease and/or a genetic disorder.
August 11: The Taiwan Strait Crisis begins with the Chinese Communist shelling of Taiwanese islands. The US backs Taiwan, and the crisis resolves itself as both sides decline to take action. September 8: Foundation of the South East Asian Treaty Organization (SEATO) by Australia, France, New Zealand, Pakistan, Thailand, the Philippines, the United Kingdom, and the United States. Like NATO, it is founded to resist Communist expansion, this time in the Philippines and Indochina. October 5: The Free Territory of Trieste is dissolved. October 10: The Jebel Akhdar War begins in Oman. November 1: The fight for independence in French Algeria begins. December 2: Sino-American Mutual Defense Treaty, is signed between the United States and the Republic of China. December 15: Surinam becomes a Dutch constituent state.
Sources: en.wikipedia.org
=== Ratings and awards === In 2005 Hibiscus was one of three restaurants to be awarded three-stars by the Egon Ronay Restaurant Guide, along with The Waterside Inn and Restaurant Tom Aikens, and was named Ronay's Restaurant of the Year. The restaurant made its first entry in the World's 50 Best Restaurants in 2010, ranked in 49th place and one of three British restaurants in the list; the following year it moved up to 43rd. The Good Food Guide ranked Hibiscus as the eighth-best restaurant in the UK in its 2013 guide. The restaurant has been given five AA Rosettes by The Automobile Association.
=== EC 2.4.99: Transferring Other Glycosyl Groups === EC 2.4.99.1: β-galactoside α-(2,6)-sialyltransferase EC 2.4.99.2: β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminide α-2,3-sialyltransferase EC 2.4.99.3: α-N-acetylgalactosaminide α-2,6-sialyltransferase EC 2.4.99.4: β-galactoside α-2,3-sialyltransferase EC 2.4.99.5: galactosyldiacylglycerol α-2,3-sialyltransferase EC 2.4.99.6: N-acetyllactosaminide α-2,3-sialyltransferase EC 2.4.99.7: α-N-acetylneuraminyl-2,3-β-galactosyl-1,3-N-acetylgalactosaminide 6-α-sialyltransferase EC 2.4.99.8: α-N-acetylneuraminate α-2,8-sialyltransferase EC 2.4.99.9: lactosylceramide α-2,3-sialyltransferase EC 2.4.99.10: Now included in EC 2.4.99.6, N-acetyllactosaminide α-2,3-sialyltransferase EC 2.4.99.11: Now included with EC 2.4.99.1,β-galactoside α-(2,6)-sialyltransferase EC 2.4.99.12: lipid IVA 3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.13: (Kdo)-lipid IVA3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.14: (Kdo)2-lipid IVA (2-8) 3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.15: (Kdo)3-lipid IVA (2-4) 3-deoxy-D-manno-octulosonic acid transferase EC 2.4.99.16: starch synthase (maltosyl-transferring) EC 2.4.99.17: S-adenosylmethionine:tRNA ribosyltransferase-isomerase EC 2.4.99.18: dolichyl-diphosphooligosaccharide—protein glycotransferase EC 2.4.99.19: undecaprenyl-diphosphooligosaccharide—protein glycotransferase EC 2.4.99.20: 2′-phospho-ADP-ribosyl cyclase/2′-phospho-cyclic-ADP-ribose transferase EC 2.4.99.21: dolichyl-phosphooligosaccharide-protein glycotransferase EC 2.4.99.22: N-acetylglucosaminide α-(2,6)-sialyltransferase
The relatively quick heteronuclear single quantum correlation experiment helps determine the feasibility of doing subsequent longer, more expensive, and more elaborate experiments. It is not possible to assign peaks to specific atoms from the heteronuclear single quantum correlation alone.
Zverev is an all-court player and does not aim to be better on any surface in particular. He has said, "I feel like I can play on all surfaces. I've been to two finals or won tournaments on every single surface. I don't feel like I have to focus on one... I feel like I have good chances at all of them." Toni Nadal, the uncle and coach of Rafael Nadal, has praised his ability on hard courts in particular, saying, "His best surface is, in my eyes, the hard court, because he moves better than he does on clay." Six of Zverev's first ten titles came on hard courts, while the other four were on clay. As of 2024, he has yet to win a title on grass, but has reached two finals and defeated Federer on that surface. His best grass tournament remains Halle, in his home country. Zverev has the ability to serve-and-volley as well. His older brother Mischa is regarded as the biggest proponent of this playing style on the modern tour. Although Zverev does not employ this technique as often as his brother, he has shown it can be effective in big matches such as the Madrid Masters final against Dominic Thiem, a player who rarely comes to the net. Zverev's volley and overhead technique are regarded as some of his biggest weaknesses. Zverev was tall but skinny and not very muscular when growing up. His fitness trainer Jez Green has focused on making him stronger and set a goal for him to add 4 kilograms (8.8 lb) of muscle each year.
Sources: en.wikipedia.org
Desmoplastic melanocytic naevus Desmoplastic spitz naevus Desmoplastic cellular blue naevus Desmoplastic hairless hypopigmented naevus Desmoplastic trichoepithelioma Desmoplastic trichilemmoma Desmoplastic tumor of the follicular infundibulum Sclerotic dermatofibroma Desmoplastic fibroblastoma Desmoplastic cellular neurothekeoma Sclerosing perineurioma Microvenular haemangioma Immature scars
A small N-terminal domain (160 amino-acid residues) A large C-terminal domain (240 amino-acid residues) Each noncovalently-associated monomer subunit consists of both domains. The subunits interact with each other through about 20 hydrogen bonds and four ion pairs, providing stability to the dimer. The two domains in each monomer subunit are more loosely connected, with only six hydrogen bonds and one ion pair between them, and no intra- or intermolecular disulfide bonds. Looking more closely at the two domains, the following structures were described in 1988:
14,810, 17 March 2008 - The SENSEX dropped by 951.03 points on the global credit crisis and distress, to fall below the 15,000 mark, closing at 14,810. The month ended with the SENSEX shedding 726.85 points on 31 March 2008, after heavy selling in blue-chip stocks on global economic fears.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.